Find a Clinical Trial

Showing 21 - 30 of 176 Trials

A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT05304585

Population:

Pediatrics/Adult

Phase:

III

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents, with approximately 350 children diagnosed annually in the United States. Patients are divided into low, intermediate, and high-risk groups based on the characteristics of their disease. The overall goals of this study are: 1. To compare the effects, good and/or bad, of giving less chemotherapy drugs to people with VLR-RMS to find out which is better. This is Arm VLR-RMS of the study. 2. To find out how well people with LR-RMS as a group respond to standard chemotherapy when risk groups are refined so...
A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with OsteosarcomaAn Intergroup NCTN Phase 3 Study

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT05235165

Population:

Pediatrics/Adult

Phase:

III

This study will be the first randomized controlled trial of surgical approach for pulmonary metastatic osteosarcoma. The study will randomize surgical resection of pulmonary metastases between Open surgery (thoracotomy or sternotomy) and minimally invasive Thoracoscopy. Primary outcome will be thoracic event free survival (thoracic event is defined as intrathoracic tumor recurrence by chest CT or death that results from the procedure or a complication related to the procedure). Correlative outcomes include quality of life from patient-reported outcomes, along with imaging and laboratory...
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT05675410

Population:

Pediatrics/Adult

Phase:

III

This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60 years with newly diagnosed early-stage cHL and will investigate the targeted CD30-antibody drug conjugate, Brentuximab Vedotin (Bv), with PD-1 blockade (nivolumab) compared with a standard chemotherapy regimen, with or without RT Are you...
AALL 1732: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT03959085

Population:

Pediatrics/Adult

Phase:

III

AALL1732 is a Children’s Oncology Group (COG) group-wide Phase 3 study for patients between the ages of 1-25 years with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL), mixed phenotype acute leukemia (MPAL), or disseminated (Murphy stage III or IV) B-lymphoblastic lymphoma (B-LLy). Patients with HR B-ALL will be stratified into HR favorable B-ALL (HR-Fav) or HR B-ALL, and this study will assess whether the incorporation of two blocks of inotuzumab ozogamicin (InO) into a modified Berlin- Frankfurt-Münster (mBFM) chemotherapy backbone will improve the disease-free...
ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma

Principal Investigator:

Nobuko Hijiya, MD

Contact Number:

212-342-5162

NCT Number:

NCT06172296

Population:

Pediatrics/Adult

Phase:

III

This randomized study will evaluate the efficacy of a frontline chemoimmunotherapy Induction regimen versus a standard chemotherapy-only Induction regimen that reserves chemoimmunotherapy only for poor responders. This Phase 3 randomized study seeks to determine if the early addition of the anti-GD2 monoclonal antibody, dinutuximab, plus sargramostim, to standard COG Induction improves EFS for patients with newly diagnosed HRNBL. All patients will receive the same Induction Cycle 1 while their tumors undergo centralized molecular testing. Patients will then be randomized to receive either...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of

Principal Investigator:

Maria Diaz Ordonez, MD

Contact Number:

212-342-5162

NCT Number:

NCT06556563

Population:

Adult

Phase:

III

The purpose of this study is to compare the effects of pembrolizumab simultaneously with the Optune device and maintenance temozolomide (TMZ) versus placebo simultaneously with Optune and maintenance TMZ for the study treatment of newly diagnosed glioblastoma multiforme (GBM). In this study, a placebo is an inactive substance that looks the same as and is given the same way as pembrolizumab. The effects of pembrolizumab are compared to the effects of the placebo. Pembrolizumab is an immunotherapy and it works with your immune system to help fight cancer. Optune® device generates Tumor...
A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF OP-1250 MONOTHERAPY VS STANDARD OF CARE FOR THE TREATMENT OF ER+, HER2– ADVANCED OR METASTATIC BREAST CANCER FOLLOWING ENDOCRINE AND CDK 4/6 INHIBITOR THERAPY (OPERA-01)

Principal Investigator:

Julia E McGuinness, MD

Contact Number:

212-342-5162

NCT Number:

NCT06016738

Population:

Adult

Phase:

III

The purpose of this study is to learn more about the investigational study drug called OP- 1250 (palazestrant) on participants with ER+, HER2- advanced or metastatic breast cancer. OP-1250 is considered endocrine therapy (treatment that adds, blocks, or removes hormones). Estrogen is a type of hormone naturally produced by the body that helps develop and maintain female sex characteristics and the growth of bones. Estrogen can also cause certain types of breast cancer to multiply, grow, and move to different parts of the body. Estrogen works in the body by binding to proteins called estrogen...
A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

Principal Investigator:

Gulam A. Manji, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06608927

Population:

Adult

Phase:

III

The purpose of this research is to determine the safety and efficacy of investigational study drug quemliclustat (also known as AB680) in combination with chemotherapy gemcitabine and nab-paclitaxel (Gem-NP), compared to a placebo (saline solution not containing treatment drug) in combination with chemotherapy gemcitabine and nab-paclitaxel at treating participants with the type of cancer you have. Quemliclustat has not been approved by the Food and Drug Administration (FDA). Gemcitabine and nab-paclitaxel (Gem-NP) is FDA approved but not in combination with quemliclustat. This is a double-...
Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Principal Investigator:

Rajshekhar Chakraborty, MD

Contact Number:

212-342-5162

NCT Number:

NCT03937635

Population:

Adult

Phase:

III

The purpose of this study is to determine whether patients with high-risk smoldering multiple myeloma when treated with daratumumab in addition to lenalidomide and dexamethasone live longer when compared to patients with high-risk smoldering multiple myeloma patients treated with lenalidomide and dexamethasone. We would also like to know whether the period of time in which patients are free of multiple myeloma symptoms differs between the two treatment groups. Daratumumab is already approved by the FDA for use in combination with lenalidomide and dexamethasone in people who have received at...
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

Principal Investigator:

Claire Sathe, MD

Contact Number:

212-342-5162

NCT Number:

NCT06492616

Population:

Adult

Phase:

III

The purpose of this study is to test a new endocrine therapy, called elacestrant, that may stop hormones from attaching to cancer cells and helping them grow. Researchers would like to understand if switching standard treatment to elacestrant (the study drug) will help to slow down or stop the growth of cancer. Treatments for early breast cancer include endocrine therapy, also called hormone therapy. Endocrine therapies work by blocking hormones from reaching the cancer cells or by reducing the amount of hormones the body makes. Are you Eligible? (Inclusion Criteria) Must be 18 years old or...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages